Beneficial effects of high-density lipoprotein (HDL) on stent biocompatibility and the potential value of HDL infusion therapy following percutaneous coronary intervention

Jian-Di Liu, MD, PhD, Ren Gong, MD, PhD, Shi-Yuan Zhang, MD, Zhi-Peng Zhou, MD, Yan-Qing Wu, MD, PhD

Abstract
Several epidemiological studies have shown a clear inverse relationship between serum levels of high-density lipoprotein cholesterol (HDL-C) and the risk of atherosclerotic cardiovascular disease (ASCVD), even at low-density lipoprotein cholesterol levels below 70 mg/dL. There is much evidence from basic and clinical studies that higher HDL-C levels are beneficial, whereas lower HDL-C levels are detrimental. Thus, HDL is widely recognized as an essential anti-atherogenic factor that plays a protective role against the development of ASCVD. Percutaneous coronary intervention is an increasingly common treatment choice to improve myocardial perfusion in patients with ASCVD. Although drug-eluting stents have substantially overcome the limitations of conventional bare-metal stents, there are still problems with stent biocompatibility, including delayed re-endothelialization and neatherosclerosis, which cause stent thrombosis and in-stent restenosis. According to numerous studies, HDL not only protects against the development of atherosclerosis, but also has many anti-inflammatory and vasoprotective properties. Therefore, the use of HDL as a therapeutic target has been met with great interest. Although oral medications have not shown promise, the developed HDL infusions have been tested in clinical trials and have demonstrated viability and reproducibility in increasing the cholesterol efflux capacity and decreasing plasma markers of inflammation. The aim of the present study was to review the effect of HDL on stent biocompatibility in ASCVD patients following implantation and discuss a novel therapeutic direction of HDL infusion therapy that may be a promising candidate as an adjunctive therapy to improve stent biocompatibility following percutaneous coronary intervention.

Keywords: high-density lipoprotein, percutaneous coronary intervention, stent biocompatibility

1. Introduction
High-density lipoprotein (HDL) is the smallest lipoprotein particle. Its main function in lipid metabolism is reverse cholesterol transport (RCT), wherein it attracts and collects cholesterol from peripheral tissues, such as arterial walls, and delivers it to the liver for eventual excretion. In fact, cholesterol carried by HDL has earned the moniker of “good cholesterol,” as considerable evidence suggests that HDL plays a protective role against the development of ASCVD. Epidemiological studies have indicated that the plasma concentrations of both HDL-C and the major HDL apolipoprotein, apoA-I, are independent, inverse predictors of the risk of having an ASCVD event; patients with pharmacologically controlled low-density lipoprotein levels and low HDL levels are still at an increased risk of ASCVD. Furthermore, Requena et al. notes...
have suggested that patients with a short-term, drug-induced decrease in HDL-C have a moderately increased long-term risk of cardiovascular events compared with those with constant HDL-C levels.

ASCVD, a prevalent disease worldwide,[9,10] causes narrowing or occlusion of arteries (especially coronary arteries), thereby hampering myocardial perfusion. Therefore, percutaneous coronary intervention (PCI) with stent implantation to dilate the partly or fully occluded coronary artery lumen is an increasingly common treatment choice to improve myocardial perfusion in patients with ASCVD. Drug-eluting stents (DES) have been developed with the progress of stent design techniques. DES has decreased the incidence of in-stent restenosis (ISR) significantly, from 20% to 35% of bare metal stents (BMS) to about 10%, while also greatly reducing the revascularization ratio of target lesions. However, delayed endothelialization caused by locally delivered drugs from DES increases the risk of late and very late stent thrombosis (ST).[10–12] Wenaweser et al.[11] reported a 0.53% annual increase in the incidence of ST, a 3.3% cumulative incidence at 4 years, and a 5.7% rate of definite and probable ST after 4 years. Additionally, the ART-II trial showed a 9.4% rate of ST (definite, probable, or possible) among ASCVD patients with multiple vessel lesions at 5 years after DES implantation, while the 5-year major adverse cardiac and cerebrovascular event rate was 27.5%.[13] Thus, the duration of dual antiplatelet therapy (DAPT) has been gradually extended from 1 month after bare metal stenting to 6–12 months or even longer after DES implantation.[14,15] However, some patient populations with high bleeding risk are more prone to hemorrhagic complications with long-term DAPT (e.g., due to age, thrombocytope- nia, comitant use of oral anticoagulants, active cancer), so they would benefit from shortened DAPT duration to reduce the risk of bleeding complications.[16] For those patients, the DAPT duration after PCI should be shortened to 1–3 months.[17] Therefore, the optimal duration of DAPT after DES implantation is still under discussion. While clinicians worry that long-term DAPT would increase the risk of bleeding while preventing ST, they also worry that short-term DAPT may not be effective in the prevention of ST.

Multifactor regression analysis has identified stent re-endothelialization as one of the important factors that may reduce the incidence of ST. Hence, a question is raised as to how to promote stent re-endothelialization after DES implantation; thus, exploring the factors that improve stent biocompatibility following implantation is an important topic in the field of cardiology.[18,19] This research will bring important clinical benefits to ASCVD patients, especially those at high risk of bleeding.

Previous reports have shown that re-endothelialization is associated with several factors, such as diabetes mellitus,[10] baseline high-sensitivity C-reactive protein levels,[11] plaque morphology,[12] strut (design and material),[13] drug elution (release kinetics),[14] and coating polymer (material or degradation process).[15] Although HDL is widely recognized as an essential anti-inflammatory factor,[22] there are few reviews about the effect of HDL on the improvement of stent biocompatibility after PCI.

This article focuses on the beneficial effect of HDL on stent biocompatibility in ASCVD patients following implantation and discusses a novel therapeutic direction for HDL infusion therapy.

2. Effects of HDL on endothelial cells (ECs)

The endothelium secretes many humoral factors that regulate vasodilatation and vasoconstriction of blood vessels, modulate platelet activation, coagulation, and fibrinolysis, and affect the proliferation and differentiation of smooth muscle cells (SMCs).[27,28] Endothelial injury and dysfunction are the initial hallmarks in the pathogenesis of ISR and ST.[29–31] One of the most important products of ECs synthesized in response to different physiological stimuli is nitric oxide (NO).[28] Through the action of NO, the endothelium induces vasodilatation, attenuates thrombocyte adhesion and aggregation, and inhibits cell cycle progression of SMCs.[30] Therefore, the integrity and function of the vascular endothelium are essential for the circulatory system. In this context, HDL has been reported as an important factor in sustaining endothelial function[32–35] and protecting the endothelial structure.[36,37]

2.1. HDL protects endothelial function

A previous study reported that HDL can reverse oxidized low-density lipoprotein (ox-LDL)-induced impairment of endothelium-dependent vasodilatation by preventing lysophosphatidylcholine from acting on the endothelium and removing lysophosphatidylcholine from ox-LDL.[38] In vivo studies showed an inverse correlation between serum HDL concentration and abnormal vasodilatation induced by acetylcholine administered to the coronary arteries.[39,40] In addition, decreased expression of endothelial nitric oxide synthase (eNOS) has been shown to be associated with endothelial dysfunction.[41] Terasaka et al.[42] suggested that HDL maintains endothelial function by promoting the efflux of cholesterol and 7-oxysterols and preserving active eNOS dimer levels via ATP-binding cassette transporter ATP-binding cassette transporter G1. Moreover, sphingosine-1-phosphate (S1P), which is carried by the apolipoprotein M-containing subfraction of HDL particles, can stimulate eNOS phosphorylation and NO production by activating the phosphatidylinositol-3-kinase/Akt/eNOS pathway in ECs.[43] According to Kim et al.[44] tumor necrosis factor α (TNF-α) considerably represses eNOS expression, but the inhibition can be restored by apolipoprotein J (apoJ), which is a protein component of HDL. Furthermore, Witting et al.[45] found that serum amyloids A promoted endothelial dysfunction by decreasing NO and L-arginine bioavailability, but HDL pretreatment preserved overall endothelial function, suggesting that HDL may be protective. Moreover, previous studies have reported that isolated low HDL is associated with endothelial dysfunction, and rapid reconstituted HDL (rHDL) infusion results in a complete restoration of vasomotor responses to both serotonin and N’-monomethyl-L-arginine by increasing NO bioavailability.[46,47] Also, HDL has a stimulatory effect on prostacyclin (PGI2) production by ECs.[48,49] PGI2 has a vasorelaxing effect and diminishes the activation of platelets, and inhibits the release of growth factors, such as fibroblast growth factor, which stimulates proliferation of SMCs.[51] However, a strong inflammatory component is involved in the pathogenesis of endothelial dysfunction. With the appearance of proinflammatory stimuli, ECs are activated and increase the abundance of adhesion molecules on their surfaces, such as E-selectin, vascular adhesion molecule-1, and intercellular cell adhesion molecule-1, which leads to the recruitment of proinflammatory immune cells to the vascular wall.[52] Some in vitro studies[44,53] have shown that HDL-associated S1P and apoJ significantly decrease the surface abundance of the 3 cell adhesion molecules through repression of the TNF-α/nuclear factor-kB (NF-kB) signaling pathway, suggesting that HDL/apolipoprotein M/S1P and apoJ not only maintain normal endothelial function under basal conditions[44] but also maintain endothelial barrier integrity under inflammatory conditions. Therefore, the beneficial effect of HDL on endothelial function was remarkable (Fig. 1).

2.2. HDL promotes re-endothelialization

Disintegration of the endothelium occurring after stent implantation induces the accumulation of platelets, the growth of SMCs, the chemoattraction of leukocytes, and several other processes, all of which ultimately lead to the occlusion of target vessels. Thus, the recovery of endothelial integrity is of immense
importance in ASCVD patients following PCI treatment. It has been shown in vitro that HDL stimulates EC migration and promotes re-endothelialization in an NO-independent manner via scavenger receptor B type I-mediated activation of Rac GTPase (Fig. 2A).[55] Tamagaki et al.[37] investigated the effects of HDL on intracellular pH and on the proliferation of human vascular ECs. They showed that HDL promoted EC proliferation via the alkalinization of intracellular pH; the alkalinization effect was mediated by phosphatidylinositol-specific phospholipase C, which cleaves phosphatidylinositol-(4,5)-bisphosphate [PI(4,5)P2], thereby increasing the release of calcium from intracellular storage sites and activating the sodium–proton antiport (Fig. 2B).[37] Additionally, Vanags et al.[56] found that apoA-I infusion increased the number of ECs in a murine model of stenting, suggesting that apoA-I promotes re-endothelialization via enhancement of endothelial progenitor cell mobilization.[57]

2.3. HDL reduces neointimal hyperplasia

Neointimal hyperplasia is characterized by the uncontrolled proliferation and migration of SMCs, which results in narrowing of the luminal area and eventual stent failure.[58,59] Previous studies have shown that vascular SMC proliferation is enhanced by the inflammatory chemokines CCL2, CCL5, and CX3CL1.[47,60–63] Some in vitro and in vivo studies have demonstrated that HDL can inhibit these chemokines[64–68] by inhibiting the intracellular NF-κB pathways,[69] and that it can also suppress SMC proliferation directly by suppressing extracellular signal-regulated kinase phosphorylation.[69] In addition, apoJ can inhibit SMC proliferation via induction of G1 cell cycle arrest accompanied by reduced retinoblastoma protein phosphorylation by down-regulating cell cycle-promoting factors (cyclins D and E) and upregulating the p53–p21 (inhibitory proteins) pathway.[44] Moreover, a previous study has reported that SMCs cause phenotypic changes regulated at the mRNA level in hyperlipidemic conditions, resulting in differentiation into macrophage-like cells; these effects are accompanied by a decreased expression of SMC α-actin.[70] Given that macrophages promote the release of growth factors and cytokines that accelerate vascular SMC proliferation, they induce neointimal hyperplasia.[71] Rong et al.[70] suggested that cellular cholesterol content might play an essential role in determining the SMC phenotype, and α-actin+ SMCs may diminish the inflammatory response in the formation of neointima. Another in vivo study demonstrated that apoA-I infusion reduces in-stent neointimal hyperplasia in a murine stent model.[56] This finding suggests that apoA-I may preserve the SMC phenotype and prevent a switch into a more macrophage-like state by increasing cholesterol efflux from neointimal SMCs,[70–72] which could create a less inflammatory environment and decrease the risk of ISR (Fig. 3).

2.4. HDL inhibits apoptosis of ECs

An in vitro study has shown that HDL prevents the apoptosis of ECs induced by TNF-α by inhibiting CPP32-like protease activity.[73] Similar observations have been reported by Suc et al.[16] and de Souza et al.[74] who found that HDL increased the resistance of ECs against ox-LDL and prevented its toxic effect by blocking the pathogenic intracellular signaling (culminating in sustained calcium rise) involved in cell apoptosis. In addition, Zhang et al.[75] suggested that HDL might significantly reduce the apoptosis of ECs via the suppression of caspase-3 activity. Furthermore, a study demonstrated that HDL protected ECs against growth factor deprivation-induced apoptosis, indicating that HDL and the associated S1P switched off the proapoptotic protein Bad via Akt stimulation, which led to the inhibition of the generation of reactive oxygen species, the dissipation of mitochondrial potential, and the release of cytochrome C into the cytoplasm, thereby preventing the activation of caspase-3 and -9 and apoptotic alterations of the plasma membrane.[76] In addition, apoJ can diminish TNF-α-induced apoptosis of ECs by inhibiting the TNF-α/NF-kB signaling pathway.[44] Both S1P

![Figure 1. The effects of high-density lipoprotein on endothelial dysfunction. ABCG1 = ATP-binding cassette transporters G1, ApoJ = apolipoprotein J, ApoM = apolipoprotein M, ECs = endothelial cells, eNOS = endothelial nitric oxide synthase, HDL = high-density lipoprotein, ICAM-1 = intercellular cell adhesion molecule-1, LPC = lysophosphatidylcholine, NO = nitric oxide, ox-LDL = oxidized low-density lipoprotein, PGI2 = prostacyclin, P38K = phosphatidylinositol 3-kinase, S1P = sphingosine-1-phosphate, TNF-α = tumor necrosis factor α, VCAM-1 = vascular adhesion molecule-1.](image-url)
2.5. HDL protects ECs from the damage brought by the activation of complement system

ECs are exposed to activated complement during local or systemic inflammation, which causes membrane deposition of C5b-9 complexes. Perturbation of the plasma membrane by these proteins results in cell lysis or nonlytic alteration of cell function. Hamilton et al. reported that deposition of C5b-9 complexes on human ECs leads to an influx of extracellular calcium, activation of secretion of von Willebrand factor, and transient expression of P-selectin. Therefore, the activated complement system results in increased neutrophil, monocyte, and platelet adhesion, as well as increased thrombin generation, causing intravascular hypercoagulability, which increases the risk of ST.

In addition, a clinical trial reported a significant increase in plasma levels of C5b-9 in patients with hypercholesterolemia compared with normoglycemic ASCVD patients and normal subjects, and the C5b-9 terminal complement complex levels were inversely correlated with HDL-C levels. In vitro studies have demonstrated that apoA-I and apoA-II inhibit complement complex-mediated cell lysis, because they can bind to the C9 complement factor and inhibit the formation of the C5b-9 terminal complement complex by interfering with the insertion of C9 into the lipid bilayer or with polymerization of C9 at C5b-8 sites. Additionally, apoJ is an inhibitor of the terminal complement complex, which inhibits C5b-9 terminal complement complex-mediated cell lysis in a concentration-dependent manner. It exerts an inhibitory effect by interacting with a structural motif common to C7, C8, and C9b. Thus, HDL may attenuate endothelial damage resulting from complement activation.

3. Effect of HDL on platelet activation

Given that platelet activation plays an important role in the formation of ST, prolonged DAPT results in a significant reduction in the rate of ST, and Naqvi et al. reported that HDL-C is a significant independent predictor of platelet-dependent thrombus formation. An epidemiological study has shown that low HDL levels are an important predictor of major cardiac events, including death, resulting from ST in patients following DES implantation. Therefore, researchers have suggested that HDL may inhibit platelet activation through various mechanisms.

A clinical trial has shown that platelet reactivity is significantly inhibited in rHDL-infused patients with diabetes mellitus via the reduction of P-selectin. This observation is in accordance with a study on a murine stent model that demonstrated that apoA-I infusion suppressed P-selectin activation. In vitro
studies have shown that HDL suppresses adrenalin-, collagen-, ADP-, and thrombin-induced platelet aggregation, suggesting that this action is mediated by an increase in NO synthase activity in platelets. HDL also inhibits thrombin-induced fibrinogen binding and aggregation on platelets by inhibiting phosphatidylinositol 4,5-bisphosphate turnover, 1,2-diacylglycerol and inositol 1,4,5-trisphosphate formation, and intracellular calcium mobilization. Desai et al. demonstrated that HDL impairs platelet responsiveness to exogenous agonists via occupation of cell-surface receptors by HDL-E particles. Moreover, Sugatani et al. found that HDL reduces the accumulation of platelet-activating factor by inhibiting platelet-activating factor synthesis, which is mediated via the suppression of acetyl-CoA:1-alkyl-2-lyso-sn-glycero-3-phosphocholine acetyltransferase activation. In addition, HDL prevents platelet hyperreactivity by limiting intraplatelet cholesterol overload, but also by modulating platelet signaling pathways after binding to the platelet HDL receptors scavenger receptor B type I and apoE receptor 2. Moreover, HDL stimulates the endothelial production of NO and PGI2, which are potent inhibitors of platelet activation. Unfortunately, decreased serum levels of HDL-C are commonly encountered in ASCVD patients, and experts have reached a consensus on the point that low serum HDL-C (<1.0 mmol/L) is an independent risk factor for ASCVD. Thus, the use of HDL as a therapeutic target has been of great interest. After 3 orally active HDL-raising agents, including niacin and 2 cholesteryl ester transfer protein inhibitors, failed in prospective intervention trials, experts proposed a change in the target of HDL therapy from elevation of circulating HDL-C levels to promote the functional properties of HDL. Thus, the focus shifted to HDL infusion therapy, which can transiently increase the number of HDL particles and thereby enhance RCT. Three important HDL formulations have been clinically evaluated. The first agent is MDCO-216 (and its precursor ETC-216), also known as apoA-I Milano, which is a naturally occurring genetic mutation in apoA-I. This variant has been found to have a shortened lifetime in the plasma, which causes faster catabolism of apoA-I, thereby increasing the amount of lipid-poor apolipoprotein present in plasma and increasing RCT capabilities. Thus, recombinant apoA-I Milano was developed for infusion. Small intravascular ultrasound (IVUS) clinical trials (47–60 patients) have compared the effect of ETC-216 or placebo on coronary atheroma burden, and showed that infusions of apoA-I Milano in patients with coronary artery disease significantly reduced coronary plaque volume (1%–2% relative to placebo) and were safe and generally well.

4. Discussion
HDL can sustain vascular endothelial function, enhance re-endothelialization, inhibit neointimal hyperplasia, protect endothelial integrity, and reduce inflammatory response and platelet activation, indicating that it plays an important role in the prevention of ISR and ST. Thus, HDL is important for ASCVD patients, especially for those who undergo PCI treatment with stent implantation.

Figure 3. The effect of high-density lipoprotein on neointimal hyperplasia. ApoJ = apolipoprotein J, ERK = extracellular signal-regulated kinase, HDL = high-density lipoprotein, IκBα = inhibitor of NF-κB, NF-κB = nuclear factor-xB, PI3K = phosphatidylinositol 3-kinase, pRb = retinoblastoma protein, SMCs = smooth muscle cells, SR-BI = scavenger receptor B type I, TNF-α = tumor necrosis factor α.
tolerated.\textsuperscript{[116,117]} However, a double-blind, randomized, multicenter trial has compared the effects of 5 weekly intravenous infusions of MDCO-216 at a dose of 20 mg/kg weekly (n = 59) with placebo (n = 67) in statin-treated patients with acute coronary syndrome (ACS). The results showed that MDCO-216 infusion did not produce an incremental plaque regression.\textsuperscript{[118]}

The second agent is CER-001, which is an artificial HDL-mimetic composed of human recombinant human apoA-I and 2 naturally occurring phospholipids. In a smaller human study, patients with familial hypoalphalipoproteinemia were given 20 infusions of CER-001.\textsuperscript{[119]} After only 9 infusions, magnetic resonance imaging showed a significant increase in mobilization of cholesterol from the arterial wall. Six months after infusions, there were significant increases in the amounts of apoA-I, HDL, and free cholesterol.\textsuperscript{[119]} A clinical trial compared the effect of 6 weekly infusions of CER-001 (3, 6, and 12 mg/kg) versus placebo on coronary atherosclerosis in 369 ACS patients using IVUS, and found that infusions of 3 mg/kg CER-001 induced the greatest atheroma regression in ACS patients with higher baseline percent atheroma volume.\textsuperscript{[120]} Nevertheless, the results of a prospective, double-blind, randomized trial conducted at 51 centers comparing the effect of 6 weekly infusions of CER-001 (3, 6, and 12 mg/kg) versus placebo in 570 ACS patients showed that CER-001 infusions did not reduce coronary atherosclerosis.\textsuperscript{[121]} Another double-blind, randomized, multicenter trial compared the effect of 10 weekly infusions of CER-001 (3 mg/kg) (n = 135) versus placebo (n = 137) in ACS patients with a high plaque burden, and the results demonstrated that infusion of CER-001 did not promote regression of coronary atherosclerosis.\textsuperscript{[122]} The third agent is CSL112 (and its precursor CSL111), which contains reconstituted formulations of human plasma-derived apoA-I and phosphatidylcholine to form synthetic HDL particles. Clinical trials have assessed the safety and pharmacokinetics/pharmacodynamics of CSL112 infusion in patients with stable atherosclerotic disease.\textsuperscript{[123,124]}

The results showed that CSL112 infusion was not only well tolerated but also immediately raised apoA-I levels and caused a rapid and marked increase in the capacity of serum to efflux cholesterol.\textsuperscript{[123,124]} In a phase II study to further evaluate the efficacy, patients were randomized to receive either CSL112 or placebo, and efficacy was assessed using IVUS and coronary angiography.\textsuperscript{[125]} Although there was no statistically significant difference between atheroma volume in CSL112 versus placebo after 4 weekly infusions, both the plaque characterization indexes and the coronary score on angiography (indexes to measure the composition of the plaque and quantify the burden of coronary artery disease, respectively) showed significant decreases compared with placebo.\textsuperscript{[125]} HDL infusion therapy can induce an acute increase in the plasma concentrations of apoA-I,\textsuperscript{[126,127]} although the effect duration is relatively short, given that the half-life of apoA-I is approximately 48 to 72 hours.\textsuperscript{[114]} It has been suggested that the intravenous administration of HDL infusion therapy is unsuitable for long-term treatment regimens because liver toxicity (as indicated by elevation of transaminases) has been observed at a higher rHDL infusion concentration in early phase trials of CSL-111.\textsuperscript{[128]} However, further studies have reported that the reformulation of HDL infusion agents (CSL-112) is well tolerated and safe, without evidence of any major organ toxicity\textsuperscript{[123,125]} indicating that the toxic effect of CSL-111 can be attributed to the excipients rather than the apoA-I component. In summary, the development of MDCO-216 and CER-001 has been discontinued because of a lack of efficacy in plaque regression in clinical trials.\textsuperscript{[129]} However, CSL112 stimulates a far more substantial increase in ABCA1-dependent cholesterol efflux capacity than that achieved in phase II studies of MDCO-216 and CER-001 (330% vs. 80%-90% and 6%, respectively), which shows a heady prospect.\textsuperscript{[124]} We believe that some negative studies do not indicate the end of the research on apoA-I-based therapeutics. We look forward to the results of the AEGIS-II phase III

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure4.png}
\caption{The effect of high-density lipoprotein on apoptosis of endothelial cells. ApoJ = Apolipoprotein J, ApoM = Apolipoprotein M, ECs = Endothelial cells, HDL = High-density lipoprotein, NF-κB = Nuclear factor-kB, ox-LDL = Oxidized low-density lipoprotein, ROS = Reactive oxygen species, S1P = Sphingosine-1-phosphate, TNF-α = Tumor necrosis factor α.}
\end{figure}
study.[130] Perhaps this large clinical trial will confirm the unique therapeutic value of CSL112.

However, previous animal studies and clinical trials related to HDL infusion therapies have focused on the stabilization of plaques and regression of atherosclerosis,[119,121,131–134] while few studies have focused on the value of HDL infusion therapy as an adjunctive therapy to promote post-PCI recovery of target vessels. To date, only Vanags et al.[116] and Kaul et al.[133] have reported the potential value of HDL infusion following BMS implantation. Although the 2 studies were animal studies and not clinical trials, the results were groundbreaking.

Over the last 2 decades, improvements in interventional techniques, refinements in stent design (particularly the advent of DES), and adjunctive DAPT have resulted in a remarkable reduction in the overall rates of stent failure. However, although the technology of DES design continues to improve, unresolved problems related to stent biocompatibility persist, including delayed re-endothelialization and neatherosclerosis, which cause ST and ISR.[136] Although first-generation DES were efficacious in reducing ISR compared with BMS, they resulted in an increase in ST.[137] Vascular toxicity from the polymers that were not adequately biocompatible, delayed re-endothelialization, and ongoing inflammation were the most common causes of this phenomenon.[137] Second-generation DES with more biocompatible polymers, thinner, more flexible cobalt-chromium or platinum-chromium struts, and newer anti-proliferative drugs – with the 2 limus analogs (zotarolimus and everolimus) replacing paclitaxel to exhibit a wider toxic-therapeutic ratio—have markedly reduced but not eliminated ST.[138] Furthermore, neatherosclerosis is an important contributing factor to late stent-related cardiovascular events after DES deployment. The histopathological substrate of neatherosclerosis is similar to that of native atherosclerosis, which contains macrophage/foam cells, cholesterol clefts, areas of calcification, and necrotic cores.[139] It has been widely hypothesized that the underlying biological mechanisms leading to neatherosclerosis are closely related to the progression of native coronary atherosclerosis.[140] During stent deployment, as the vascular wall undergoes expansion by stent struts, endothelial denudation, significant medial injury, plaque compression, and rupture of the internal elastic lamina occur, thereby triggering an inflammatory response. Over time, plaque is capable of becoming a source of growth factors, cytokines, and chemokines, thereby promoting neatherosclerosis.[140] Neatherosclerosis occurs within a much shorter time frame than native atherosclerosis at 6 months to 5 years after stent deployment.[141] Neatherosclerosis accelerates the late expansion of the neointima as a key cause of stent failure. Neointimal plaques can also become unstable, with ruptured thin-capped neointimal plaques acting as the primary cause of very late ST.[142] Although the mechanisms of neatherosclerosis have not been entirely elucidated, the higher occurrence of neatherosclerosis in DES may be the result of drug resistance, a reaction to the DES polymers, or DES-induced delayed re-endothelialization.[142] Therefore, the addition of novel adjunctive therapies to reduce these risks remains crucial.

Numerous previous studies have documented the beneficial effects of HDL on blood vessels[16,31,127] and the safety of HDL infusion therapies,[123,125] suggesting that the HDL infusion may be a promising therapy to improve stent biocompatibility for ASCVD patients with DAPT intolerance after stenting. However, no clinical trials thus far have demonstrated the benefits of HDL infusion for ASCVD patients who underwent PCI treatment. Large clinical trials of HDL infusion should be conducted in these patients; however before that, researchers have to make a very detailed proposal about the single dose and treatment duration of HDL infusion therapy after DES implantation. Overall, HDL formulations delivered via infusion represent a new modality of adjunctive therapy following PCI, which is a novel research direction.

5. Conclusion

HDL has a number of beneficial effects on stent biocompatibility after PCI, such as the maintenance of vascular endothelial function, protection of endothelial integrity, enhancement of re-endothelialization, and reduction of inflammation and platelet activation. HDL infusion therapy is a promising candidate for improving stent biocompatibility following implantation. We believe that the application of HDL infusion therapy following DES implantation will greatly shorten the duration of DAPT and significantly reduce the incidence of ST. Given that there are few related studies, further studies on HDL infusions and the beneficial role of HDL in stent biocompatibility have the potential to yield better adjunctive therapy regimens following PCI.

Author contributions

Conceptualization: Jian-Di Liu, Yan-Qing Wu.
Data curation: Jian-Di Liu, Ren Gong, Shi-Yuan Zhang, Zhi-Peng Zhou.
Writing – original draft: Jian-Di Liu.
Writing – review & editing: Jian-Di Liu, Yan-Qing Wu.

References

[1] Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005;96:1221–32.
[2] Tan JT, Ng MK, Bursill CA. The role of high-density lipoproteins in the regulation of angiogenesis. Cardiovasc Res. 2015;106:184–93.
[3] Prosser HC, Tan JT, Dunn LL, et al. Multifunctional regulation of angiogenesis by high-density lipoproteins. Cardiovasc Res. 2014;101:145–54.
[4] Inazu A, Koizumi J, Mabuchi H. Cholesterol ester transfer protein and atherosclerosis.Curr Opin Lipidol. 2000;11:389–96.
[5] Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486–97.
[6] Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:169–73.
[7] Fisher EA, Feig JE, Hewing B, et al. High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 2012;32:2813–20.
[8] Requena G, Ma L, Sturmer T, et al. Association between an acute, drug-induced decrease in high-density lipoprotein cholesterol levels and risk of cardiovascular events. Clin Drug Investig. 2020;40:747–54.
[9] Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics–2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–322.
[10] Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369:67–78.
[11] Wenaweser P, Daemen J, Zwahlen M, et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol. 2008;52:1134–40.
[12] Windlecker S, Meier B. Late coronary stent thrombosis. Circulation. 2007;116:1952–65.
[13] Serruys PW, Onuma Y, Garg S, et al. 5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. J Am Coll Cardiol. 2010;55:1093–101.
[14] Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2016;68:1082–115.
[15] Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology
[36] Costa F, Van Klaveren D, Feres E, et al. Dual antiplatelet therapy duration based on acute myocardial infarction: a new red flag is raised. Circulation. 2008;118:1117–9.

[36] Benezet-Mazuecos J, Itbanez B, Badimon JJ. Dual antiplatelet therapy and drug eluting stents: a mating of convenience. Thromb J. 2007;5:15.

[36] Tanaka N, Terashima M, Rathore S, et al. Different patterns of vascular response between patients with or without diabetes mellitus after drug-eluting stent implantation: optical coherence tomographic analysis. JACC Cardiovasc Interv. 2010;3:1074–9.

[31] Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late atherothrombosis: strut coverage as a marker of endothelialization. Circulation. 2007;111:1619–26.

[31] Soucy NV, Feygin JM, Tunstall R, et al. Strut tissue coverage and endothelial cell coverage: a comparison between bare metal stent platforms and platinum chromium stents with and without everolimus-eluting coating. Eurointervention. 2010;6:357–61.

[31] Guagliumi G, Ikejima H, Sirbu V, et al. Impact of drug release kinetics on vascular response to different zotarolimus-eluting stents implanted in patients with long coronary stenoses: the LongOCT study (optical coherence tomography in long lesions). JACC Cardiovasc Interv. 2011;4:778–85.

[34] Guagliumi G, Sirbu V, Musumeci G, et al. Strut coverage and vessel wall response to a new-generation paclitaxel-eluting stent with an ultrathin biodegradable ablumin polymer: optical coherence tomography drug-eluting stent investigation (OCTDESI). Circ Cardiovasc Interv. 2010;3:367–75.

[34] Nofer JR, Kehrel B, Fokker M, et al. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis. 2002;161:1–16.

[34] Tohorek M, Kaiser S. Endothelial cell functions. Relationship to atherogenesis. Basic Res Cardiol. 1999;94:295–314.

[34] Bieglens ES, Losalzalio J. Endothelial function and atherosclerosis. Corron Artery Dis. 1999;10:241–56.

[34] Sima AV, Stanicu CS, Simionescu M. Vascular endothelium in atherosclerosis. Cell Tissue Res. 2009;335:191–203.

[34] van Oostrom O, Nieuwdorp M, Westerweel PE, et al. Reconstituted high-density lipoprotein on endothelium-dependent vasodilatation. Int J Cardiol. 2009;134:9–15.

[34] Seetharam D, Mineo C, Gormley AK, et al. High-density lipoprotein-associating proteins on intracellular pH and proliferation of human vascular endothelial cells. Atherosclerosis. 1996;125:73–82.

[34] Matsuda Y, Hirata K, Inoue N, et al. High density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on endothelium-dependent arterial relaxation. Circ Res. 1993;72:1103–9.

[34] Kuhn FE, Mohler ER, Satler LF, et al. Effects of high-density lipoprotein on acetylcholine-induced coronary vasoactivity. Am J Cardiol. 1991;68:1425–30.

[34] Zehir AM, Schachlinger V, Hohlocher SH, et al. Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation. 1994;89:325–32.

[34] Sharifi F, Hynes SO, Cooney R, et al. Gene-eluting stents: adenovirus-mediated delivery of eNOS to the blood vessel wall accelerates re-endothelialization and inhibits restenosis. Mol Ther. 2008;16:1674–80.

[34] Terasaka N, Yu S, Yvan-Chavet L, et al. ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet. J Clin Invest. 2008;118:3701–13.

[34] Rikitake Y, Hirata K, Kawashima S, et al. Involvement of endothelial nitric oxide in sphingosine-1-phosphate-induced angiogenesis. Arterioscler Thromb Vasc Biol. 2002;22:108–14.

[34] Kim HJ, Yoo EK, Kim JY, et al. Protective role of clusterin/apolipoprotein J against neointimal hyperplasia via antiproliferative effect on vascular smooth muscle cells and cytoprotective effect on endothelial cells. Arterioscler Thromb Vasc Biol. 2009;29:1558–64.

[34] Witting PK, Song C, Hsu K, et al. The acute-phase protein serum amyloid A induces endothelial dysfunction that is inhibited by high-density lipoprotein. Free Radic Biol Med. 2011;51:1390–8.

[34] Bisodeal RJ, Hovingh GK, Levels JH, et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation. 2003;107:2944–8.

[34] Selzman CH, Miller SA, Zimmerman MA, et al. Monocyte chemotactic protein-1 directly induces human vascular smooth muscle proliferation. Am J Physiol Heart Circ Physiol. 2002;283:H1453–61.

[34] Niewoehr M, Vergeer M, Bisodeal RJ, et al. Reconstituted HDL inversely correlates with end-stage function in patients with type 2 diabetes mellitus. Diabetologia. 2008;51:1081–4.

[34] Beitz A, Beitz J, Mest HJ. Is the antitherosclerotic potency of HDL modulated by the origin of HDL? Prostaglandins Leukot Essent Fatty Acids. 1994;50:115–21.

[34] Cockvelopi GW, Saklatvala J, Ridley SH, et al. High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2. Arterioscler Thromb Vasc Biol. 1999;19:910–7.

[34] Vinals M, Martinez-Gonzalez J, Badimon JJ, et al. HDL-induced pros-tacyclin release in smooth muscle cells is dependent on cyclooxygenase-2 (Cox-2). Arterioscler Thromb Vasc Biol. 1997;17:3481–8.

[34] Spagnoli LG, Bonanno E, Sangiorgi G, et al. Role of inflammation in arteriosclerosis. J Nucl Med. 2007;48:1800–15.

[34] Ruiz M, Frej C, Holmer A, et al. High-density lipoprotein-associated apolipoprotein M limits endothelial inflammation by delivering sphingosine-1-phosphate to the sphingosine-1-phosphate receptor 1. Arterioscler Thromb Vasc Biol. 2017;37:118–29.

[34] Wilkerson BA, Grass GD, Wing SB, et al. Sphingosine 1-phosphate (SIP) carrier-dependent regulation of endothelial barrier: high density lipoprotein (HDL)-SIP promotes endothelial barrier enhancement as compared with albumin-SIP via effects on levels, trafficking, and signaling of SIP1. J Biol Chem. 2012;287:44645–53.

[34] Seetharam D, Mineo C, Gormley AK, et al. High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ Res. 2008;96:63–72.

[34] Vanags LZ, Tan J, Galouzaki KK, et al. Apolipoprotein A-I prevents in-stent restenosis and platelet activation and alters neointimal cellular phenotype. JACC Basic Transl Sci. 2018;3:220–9.

[34] van Oostrom O, Nieuworp M, Westerweel PE, et al. Reconstituted HDL increases circulating endothelial progenitor cells in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol. 2007;27:1864–5.

[34] Korsowski R, Hong MK, Tio FO, et al. Impact of inflammation on vascular response between patients with or without diabetes mellitus after drug-eluting stent investigation (OCTDESI). Circ Cardiovasc Interv. 2010;3:367–75.

[34] Finn AW, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007;115:2435–41.

[34] Li XP, Zhao SP, Zhang XY, et al. Protective effect of high density lipoprotein on endothelium-dependent vasodilatation. Int J Cardiol. 2000;73:231–6.

[34] Zhang X, Zhao SP, Li XG, et al. Endothelium-dependent and -independent functions are impaired in patients with coronary heart disease. Atherosclerosis. 2000;149:19–24.

[34] Tokkka JO, Ahotupa M, Viikari JS, et al. Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men. Atherosclerosis. 1999;147:133–8.

[34] Sattar N, Petrie JR, Jaap AJ. The atherogenic lipoprotein phenotype and vascular endothelial dysfunction. Atherosclerosis. 1998;138:229–35.

[34] Suc I, Escargueil-Blanc I, Troyo M, et al. HDL and ApoA prevent cell death of endothelial cells induced by oxidized LDL. Arterioscler Thromb Vasc Biol. 1997;17:2158–66.

[34] Tamagaki T, Sawada S, Imamura H, et al. Effects of high-density lipoprotein on intracellular pH and proliferation of human vascular endothelial cells. Atherosclerosis. 1996;125:73–82.

[34] Matsuda Y, Hirata K, Inoue N, et al. High density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on endotheli-um-dependent arterial relaxation. Circ Res. 1993;72:1103–9.

[34] Kuhn FE, Mohler ER, Satler LF, et al. Effects of high-density lipopro-tein on acetylcholine-induced coronary vasoactivity. Am J Cardiol. 1991;68:1425–30.
[89] Naqvi TZ, Shah PK, Ivey PA, et al. Evidence that high-density lipoprotein (HDL) and cardiovascular risk? Nat Med. 2012;18:1344–6.

[90] Wolfram RM, Brewer HB, Xue Z, et al. Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation. Am J Cardiol. 2006;98:711–7.

[91] Calkin AC, Drew BG, Ono A, et al. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation. 2009;120:2095–104.

[92] Aviram M, Brook JG. Characterization of the effect of plasma lipoproteins on platelet function in vitro. Haemostasis. 1983;13:344–50.

[93] Aviram M, Brook JG. Platelet interaction with high and low density lipoproteins. Arterioscler. 1985;5:353–64.

[94] Hassell NG, Owen JS, Bruckdorfer KR. The aggregation of isolated human platelets in the presence of lipoproteins and prostacyclin. Biochem J. 1993;216:43–9.

[95] Pajkrt D, Lerch PG, van der Poll T, et al. Differential effects of reconstituted high-density lipoprotein on coagulation, fibrinolysis and platelet activation during human endotoxemia. Thromb Haemost. 2003;90:568–75.

[96] Leung K, Yueh B, Wolinska I, et al. Impact of high-density lipoprotein on the apoptosis of endothelial cells induced by oxidized low-density lipoprotein. Sichuan Da Xue Xue Bao Yi Xue Ban. 2003;34:67–9.

[97] Nofer JR, Walter M, Kehrel B, et al. HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-trisphosphate. Arterioscler Thromb Vasc Biol. 1998;18:861–9.

[98] Desai K, Bruckdorfer KR, Hutton RA, et al. Binding of apoAII high density lipoprotein particles by saturable sites on human blood platelets inhibits agonist-induced platelet aggregation. J Lipid Res. 1989;30:831–40.

[99] Sugatan J, Miwa M, Komiyama Y, et al. High-density lipoprotein inhibits the synthesis of platelet-activating factor in human vascular endothelial cells. J Lipid Mediat Cell Signal. 1996;13:73–88.

[100] Verger M, Korporaal SJ, Franssen R, et al. Genetic variant of the scavenger receptor BI in humans. N Engl J Med. 2011;364:136–45.

[101] Uittenbogaard A, Shafl PW, Yuhanna IS, et al. High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J Biol Chem. 2000;275:11278–83.

[102] Dangel O, Mergel P, Karlsch K, et al. Nitric oxide-sensitive guanylyl cyclase is the only nitric oxide receptor mediating platelet inhibition. J Thromb Haemost. 2010;8:1343–52.

[103] Toth PP. High-density lipoprotein and cardiovascular risk. Circulation. 2004;109:1809–12.

[104] Di Angelantonio E, Sarwar N, Perry P, et al. Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993–2000.

[105] Catarano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37:2999–3058.

[106] Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2525–67.

[107] Group HTCC. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279–91.

[108] Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–22.

[109] Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089–99.

[110] Rader DJ, Tall AR. The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis? Nat Med. 2012;18:1344–6.

[111] Vucic E, Rosenson RS. Recombinant high-density lipoprotein formulations. Curr Atheroscler Rep. 2011;13:81–7.
[114] Kingwell BA, Chapman MJ. Future of high-density lipoprotein infusion therapies: potential for clinical management of vascular disease. Circulation. 2013;128:1132–21.

[115] Li D, Weng S, Yang B, et al. Inhibition of arterial thrombus formation by ApoA-I Milano. Arterioscler Thromb Vasc Biol. 1999;19:378–83.

[116] Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292–300.

[117] Nicholls SJ, Tuzcu EM, Sipahi I, et al. Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano. J Am Coll Cardiol. 2006;47:992–7.

[118] Nicholls SJ, Puri R, Ballantyne CM, et al. Effect of infusion of high-density lipoprotein mimetic containing recombinant apolipoprotein A-I Milano on coronary disease in patients with an acute coronary syndrome in the MILANO-PILOT trial: a randomized clinical trial. JAMA Cardiol. 2018;3:806–14.

[119] Kootte RS, Smits LP, van der Valk FM, et al. Effect of open-label infusion of an apolipoprotein A-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA. J Lipid Res. 2013;56:703–12.

[120] Kataoka Y, Andrews J, Duong M, et al. Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden. Cardiovasc Diagn Ther. 2017;7:252–63.

[121] Tardif JC, Ballantyne CM, Barter P, et al. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J. 2014;35:2777–86.

[122] Nicholls SJ, Andrews J, Kastelein J, et al. Effect of serial infusions of CER-001, a Pre-beta high-density lipoprotein mimetic, on coronary atherosclerosis in patients following acute coronary syndromes in the CER-001 atherosclerosis regression acute coronary syndrome trial: a randomized clinical trial. JAMA Cardiol. 2018;3:815–22.

[123] Tricoci P, D’Andrea DM, Gurbel PA, et al. Infusion of reconstituted high-density lipoprotein, CSL112, in patients with atherosclerosis: safety and pharmacokinetic results from a phase 2a randomized clinical trial. J Am Heart Assoc. 2015;4:e2171.

[124] Michael GC, Korjian S, Tricoci P, et al. Safety and tolerability of CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I, after acute myocardial infarction: the AEGIS-I trial (ApoA-I Event Reducing in Ischemic Syndromes I). Circulation. 2016;134:1918–30.

[125] Easton R, Gille A, D’Andrea D, et al. A multiple ascending dose study of CSL112, an infused formulation of ApoA-I. J Clin Phamacol. 2014;54:301–10.

[126] Nanjee MN, Doran JE, Lerch PG, et al. Acute effects of intravenous infusion of ApoA1/phosphatidylcholine discs on plasma lipoproteins in humans. Arterioscler Thromb Vasc Biol. 1999;19:979–89.

[127] Patel S, Drew BG, Nakha S, et al. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J Am Coll Cardiol. 2009;53:962–71.

[128] Tardif JC, Gregoire J, L’Allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 2007;297:1675–82.

[129] Kingwell BA, Nicholls SJ, Velkoska E, et al. Antiatherosclerotic effects of CSL112 mediated by enhanced cholesterol efflux capacity. J Am Heart Assoc. 2022;11:e24754.

[130] Rader DJ. Apolipoprotein A-I infusion therapies for coronary disease: two outs in the ninth inning and swinging for the fences. JAMA Cardiol. 2018;3:799–801.

[131] Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711–8.

[132] Briel M, Schwartz GG, Thompson PL, et al. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA. 2006;295:2046–56.

[133] Waksman R, Torguson R, Kent KM, et al. A first-in-man, randomized, placebo-controlled trial to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol. 2010;55:2727–35.

[134] Borthwick F, Wannakula S, Mangat R, et al. ApoA-I infusion reduces arterial cholesterol and myocardial lesions in a rat model of cardiac dysfunction and insulin resistance. Atherosclerosis. 2012;222:402–8.

[135] Kaul S, Rukshin V, Santos R, et al. Intramural delivery of recombinant apolipoprotein A-IMilano/phospholipid complex (ETC-216) inhibits in-stent stenosis in porcine coronary arteries. Circulation. 2003;107:2551–4.

[136] Byrne RA, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Gruntzig Lecture ESC 2014. Eur Heart J. 2015;36:3320–31.

[137] Stone GW, Ellis SG, Colombo A, et al. Long-term safety and efficacy of paclitaxel-eluting stents final 3-year analysis from the TAXUS Clinical Trial Program. JACC Cardiovasc Interv. 2011;4:530–42.

[138] Kereiakes DJ, Smits PC, Edel E, et al. Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials. Eurointervention. 2011;7:74–83.

[139] Otsuka F, Byrne RA, Yahagi K, et al. Neatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. Eur Heart J. 2015;36:2147–59.

[140] Tanikawa M, Windecker S, Zauag S, et al. The association between in-stent neatherosclerosis and native coronary artery disease progression: a long-term angiographic and optical coherence tomography cohort study. Eur Heart J. 2015;36:2147–59.

[141] Ravindran D, Galoughahi KK, Tan J, et al. The multiple roles of chemokines in the mechanisms of stent biocompatibility. Cardiovasc Res. 2021;117:2299–308.

[142] Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol. 2011;57:1314–22.